Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$4.70
▼ $0.04 (-0.8%)
Market data updated: 09/21 09:59 PM
Fundamentals updated: 09/21/2026
News analyzed: 09/21/2026
Market Cap
$195.51M
Day Range
$4.67 - $4.76
52-Week Range
$2.09 - $5.47
Beta
—
Next Earnings
11.11.2026
Support
$3.91
Resistance
$5.47
ORMP is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+100.9% (1Y)
Strengths: 13/27 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 412.5%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$2.85 vs. price $4.70 (-160.7%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
56
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
60
Quality
42
Value
48
Momentum
52
Risk
40
Sentiment
92
Fundamental
58
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Oramed Pharmaceuticals Inc. highlights financial and strategic milestones, including its inclusion in the **Russell 2000 and 3000 indexes**, which analysts suggest could boost investor awareness and stock visibility. The company also reported strong **second-quarter earnings**, repayment of a Scilex loan, and a strengthened balance sheet. Additionally, Oramed secured **up to $11.2 million in strategic financing** through Lifeward to support commercial expansion, alongside leadership changes at its parent company, Lifeward.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Oramed Pharmaceuticals Inc.. News trend score: 92. Reason: 8 of the last 15 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
32
🎯 Conviction (vs. Emotion)
48
Psychology
37
Fundamentals
58
Technical
52
Valuation
48
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+13%
Market Narrative
52
Fundamental Reality
48
Narrative Gap
+4
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
ORMP’s psychology score of 35 is dominated by **euphoria**, as strong momentum (+4.6% ROC), a 22.1% premium over its 200-day average, and high sentiment (86/100) create a narrative of sustained optimism. FOMO (28) lingers due to positive momentum and volume, but panic (2) and overconfidence (1) remain subdued. The **narrative gap (16)** suggests traders may be overestimating growth potential relative to fundamentals. The key question: *Is this momentum self-sustaining, or will reality (EPS growth at +4.1%) eventually temper euphoria?*
Updated: 09/07/2026, 04:19 PM
What could change this?
👥 What the crowd believes
"View inclusion in Russell Indexes as positive that could raise awareness in investment community"
"Lifeward Enters Securities Purchase Agreement Under Oramed Financing Framework"
"Highlighting... a Strengthened Balance Sheet"
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock divides historical methodologies sharply, with some seeing it as a rare opportunity and others flagging it as a high-risk or overvalued bet. The highest scores come from **Bagehot** (100) and **Graham** (99), both praising its liquidity and statistical undervaluation—suggesting a defensive or credit-resistant play. Meanwhile, **Lynch** and **Enterprising Graham** (both 86) highlight its growth potential, though with a more speculative edge. In contrast, **Livermore** (62) and **Schwager** (49) see no clear trend or edge, while **Mackay** (47) and **Veblen** (42) warn of speculative crowd behavior or uncertain profitability. The most bearish camp—**Fisher** (36), **Marks** (35), and **Malkiel/Bogle** (30)—dismiss it as lacking quality, growth, or efficiency, while **Housel** (0) sees it as volatile enough to deter patient long-term holders. The divide reflects whether the stock’s fundamentals or speculative momentum justify the risk.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 87
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 86
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 79
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 52
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 42
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 42
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 39
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 36
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 35
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 34
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 29
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 29
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 25
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 283 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (4 bullish · 5 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
0.7%
Operating Margin
-754.4%
Net Margin
3202.5%
EBITDA Margin
-754.4%
ROE
32.1%
ROA
27.7%
ROIC
—
EPS
$1.53
Cash
$45.95M
Total Debt
—
Current Ratio
6.98
Debt/Equity
—
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 16.1.2026 | $0.250 |
| 15.1.2026 | $0.250 |
How is Fair Value calculated? →
Current Price
$4.70
Estimated Fair Value (DCF)
-$2.85
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-160.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
-5.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -5.0% | $-8.70M | $-7.98M |
| 2 | -3.1% | $-8.42M | $-7.09M |
| 3 | -1.2% | $-8.32M | $-6.42M |
| 4 | 0.6% | $-8.37M | $-5.93M |
| 5 | 2.5% | $-8.58M | $-5.58M |
Base FCF (last actual year)
$-9.15M
Terminal Value
$-135.31M
Present Value of Terminal Value
$-87.94M
Enterprise Value
$-120.94M
Net Debt
$0
Equity Value
$-120.94M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$4.71
Tangible Book Value per Share (Tangible NAV)
$4.71
Sentiment based on basic keywords (not AI) — 8 positive, 6 neutral, 1 negative out of the last 15 articles.
SeekingAlpha · 11.9.2026
GlobeNewswire · 8.9.2026
Yahoo · 8.9.2026
MT Newswires · 31.8.2026
Yahoo · 28.8.2026
Zacks Small Cap Research · 28.8.2026
GlobeNewswire · 17.8.2026
Associated Press · 10.8.2026
MT Newswires · 7.7.2026
GlobeNewswire · 7.7.2026
PR Newswire · 25.6.2026
Zacks Small Cap Research · 18.6.2026
PR Newswire · 17.6.2026
Simply Wall St. · 15.6.2026
Zacks Small Cap Research · 8.6.2026
Oramed Pharmaceuticals Inc. (ORMP) currently has a StockIQ AI score of 56/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ORMP currently scores 56/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ORMP's estimated fair value is -$2.85, which is 160.7% below the current price of $4.70. This is one valuation model among several signals in the fair-value category, not a price target.
ORMP's technical score is 52/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 412.5%; Net income growth: 436.0%; Return on equity (ROE): 32.1% — strong.
Based on the real signals StockIQ computed: Estimated fair value: -$2.85 vs. price $4.70 (-160.7%); Operating margin: -754.4% (negative); Operating margin is eroding over time.
Yes — ORMP has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 4 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Hexter Joshua | Exercise of Derivative Securities | 2.7.2026 | 50,000 | +50,000 | $3.69 |
| Hexter Joshua | Exercise of Derivative Securities | 2.7.2026 | 50,000 | -50,000 | — |
| Hexter Joshua | Exercise of Derivative Securities | 2.7.2026 | 1,073,384 | +50,000 | $3.69 |
| Hexter Joshua | Exercise of Derivative Securities | 2.7.2026 | 50,000 | -50,000 | — |
| Hexter Joshua | Open Market Sale | 1.7.2026 | 137,000 | -137,000 | $4.46 |
| Gabay Avraham | Open Market Sale | 1.7.2026 | 73,360 | -73,360 | $4.51 |
| Gabay Avraham | Open Market Sale | 1.7.2026 | 671,785 | -73,360 | $4.51 |
| Hexter Joshua | Open Market Sale | 1.7.2026 | 1,023,384 | -137,000 | $4.46 |
| KIDRON NADAV | Tax Withholding in Shares | 30.3.2026 | 44,818 | -44,818 | $3.31 |
| Kidron Miriam | Tax Withholding in Shares | 30.3.2026 | 435,084 | -435,084 | $3.31 |
| Kidron Miriam | Tax Withholding in Shares | 30.3.2026 | 1,133,138 | -435,084 | $3.31 |
| KIDRON NADAV | Tax Withholding in Shares | 30.3.2026 | 3,422,243 | -44,818 | $3.31 |
| Kidron Miriam | Grant/Award from Employer | 17.3.2026 | 119,558 | +119,558 | — |
| Hexter Joshua | Grant/Award from Employer | 17.3.2026 | 95,889 | +95,889 | — |
| Gabay Avraham | Grant/Award from Employer | 17.3.2026 | 95,889 | +95,889 | — |
| KIDRON NADAV | Grant/Award from Employer | 17.3.2026 | 167,005 | +167,005 | — |
| Gabay Avraham | Grant/Award from Employer | 17.3.2026 | 745,145 | +95,889 | — |
| Hexter Joshua | Grant/Award from Employer | 17.3.2026 | 1,160,384 | +95,889 | — |
| KIDRON NADAV | Grant/Award from Employer | 17.3.2026 | 3,422,243 | +167,005 | — |
| Kidron Miriam | Grant/Award from Employer | 17.3.2026 | 1,568,222 | +119,558 | — |
| KIDRON NADAV | Gift | 12.3.2026 | 100,000 | -100,000 | — |
| KIDRON NADAV | Gift | 12.3.2026 | 3,255,238 | -100,000 | — |
| Kidron Miriam | Exercise of Derivative Securities | 22.1.2026 | 19,000 | -19,000 | — |
| Gabay Avraham | Exercise of Derivative Securities | 22.1.2026 | 19,000 | +19,000 | — |
| Kidron Miriam | Exercise of Derivative Securities | 22.1.2026 | 19,000 | +19,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,154,241 shares short as of 2026-08-31 · vs. 835,493 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
46.4% of trading volume this week was short selling, vs. 54.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology